Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis

European Respiratory Journal

Volumn 14, Issue 5, 1999, Pages 1145-1149

  Eichler, I ^a   Nilsson, M ^b   Rath, R ^a   Enander, I ^b   Venge, P ^c   Koller, D Y ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b PFIZER INC   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cystic fibrosis; Human neutrophil lipocalin; Lactoferrin; Myeloperoxidase; Neutrophil activation

Indexed keywords

LACTOFERRIN; LIPOCALIN; MYELOPEROXIDASE;

ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0032720873     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.14511459     Document Type: Article

References (23)

1. Davis PB, Drumm M, Konstan MW. State of the art: Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-1256.
2. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-375.
3. Brown R, Kelly FJ. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 1994; 49: 738-742.
4. Olsson I, Venge P. The role of the human neutrophil in the inflammatory reaction. Allergy 1988; 35: 1-13.
5. Berger M. Inflammation in the lung in cystic fibrosis. In: Gershwin E, editor. Clinical Reviews in Allergy, Vol 9: Cystic fibrosis. Humana Press, 1991; pp. 119-142.
6. Triebel S, Bläser J, Reineke H, Tschesche H. A 25 kDa beta2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. Fed Eur Biochem Soc Let 1992; 314: 386-388.
7. Xu SY, Pauksen K, Venge P. Serum measurement of human neutrophil lipocalin (HNL) discriminate between acute bacteria and viral infections. Scan J Clin Lab Invest 1995; 55: 125-131.
8. Xu SY, Calson M, Engström A, Garcia R, Peterson CGB, Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophiles. Scan J Clin Lab Invest 1994; 54: 365-376.
9. Koller DY, Nilsson M, Enander I, Venge P, Eichler I. Serum measurement of eosinophil cationic protein, eosinophil peroxidase and eosinophil protein X in patients with cystic fibrosis: relation with pulmonary function. Clin Exp Allergy 1998; 28: 241-248.
10. Olsson I, Olofson T, Olofson O, Gustavsson A. Serum and plasma myeloperoxidase, elastase and lactoferrin. Scand J Haematol 1979; 22: 397-406.
11. Koller DY, Urbanek R, Götz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med 1995; 155: 1050-1054.
12. American Thoracic Society. Standardization of spirometry- 1987 update. Am Rev Respir Dis 1987; 2: 1285-1289.
13. Zapletal A, Samanek M, Paul T. Lung function in children and adolescents. Methods, reference, values. Progr Resp Res 1987; 22: 113-218.
14. Shwachman H, Kulzcycki L. Long term study of 105 patients with cystic fibrosis. Am J Dis Child 1958; 96: 6-15.
15. Moss RB. Hypergammaglobulinemia in cystic fibrosis. Chest 1987; 91: 522-526.
16. Meyer KC, Zimmermann J. Neutrophil mediators, Pseudomonas and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993; 121: 654-661.
17. Koller DY, Götz M, Eichler I, Urbanek R. Eosinophilic activation in cystic fibrosis. Thorax 1994; 49: 496-499.
18. Axelsson I, Bergenfeldt M, Olsson K. Studies of the release and turnover of human neutrophil lipocalin. Scan J Clin Lab Invest 1995; 55: 577-588.
19. Seveus L, Amin K, Peterson CGB, Roomans GM, Venge P. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in bronchial and lung parenchymal tissue and peripheral blood cells. Histochemistry and Cell Biology 1997; 107: 423-432.
20. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 1997; 155: 449-453.
21. Eichler I, Joris L, Hsu YP, van Wye J, Bram C, Moss RB. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobuline G antibodies from infected patient sera inhibit neutrophil oxidative response. J Clin Invest 1989; 84: 1794-1804.
22. Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis; correlation between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 1991; 10: 92-100.
23. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.